(Reuters) – AstraZeneca said on Friday the European Medicines Agency’s human medicines committee recommended its and Daiichi Sankyo’s Enhertu drug as a monotherapy to treat patient with a type of non-small cell lung cancer (NSCLC).
(Reporting by Khushi Mandowara in Bengaluru; Editing by Shilpi Majumdar)
